ZoniclezoleAlternative Names: CGS 18416; CGS 18416A
Latest Information Update: 10 Feb 1997
At a glance
- Originator Novartis
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 10 Feb 1997 No-Development-Reported for Epilepsy in Switzerland (Unknown route)